C. Definition: Unprofessional or dishonorable conduct by a pharmacist shall mean, among other things, but not be limited to:

1. (1) Violation of any provision of the Pharmacy Act as determined by the board.
2. (2) Violation of the board of pharmacy regulations as determined by the board.
3. (3) Violation of the Drug and Cosmetic Act as determined by the board.
4. (4) Violation of the Controlled Substances Act as determined by the board.
5. (5) Failure of the pharmacist to conduct theirself professionally in conformity with all applicable federal, state and municipal laws and regulations to their relationship with the public, other health professions and fellow pharmacists.
6. (6) Failure to keep their pharmacy and/or area of professional practice clean, orderly, maintained and secured for the proper performance of their professional duties.
7. (7) Acquiring prescription stock from unlicensed sources.
8. (8) Failure to hold on the strictest confidence all knowledge concerning patrons, their prescriptions, and other confidence entrusted or acquired of by them; divulging in the interest of the patron only by proper forms, or where required for proper compliance with legal authorities.
9. (9) Participation in a plan or agreement which compromises the quality or extent of professional services, or facilities at the expense of public health or welfare.
10. (10) The solicitation of prescription business by providing prescribers with prescription blanks with the name of any licensed pharmacy or pharmacist printed thereon.

11. (11) The solicitation of prescription business by providing a prescriber with pre-selected medication on a prescription blank. This does not apply to:

    1. (a) the inpatient, or institutional setting (i.e. long term care or correctional facility) by an in-house or contracted pharmacy; or
    2. (b) a request for therapeutic interchange of a medication prescribed for the patient;
12. (12) The solicitation of a prescription whereby the initial prescription request was not initiated by the patient or practitioner. This does not apply to a request for therapeutic interchange of a medication prescribed for the patient.
13. (13) Failure to report a theft or loss of controlled substances in accordance with 16.19.20.36 NMAC.
14. (14) Failure to report an impaired licensee in compliance with Subparagraph (a) of Paragraph (1) of Subsection C of 16.19.4.12 NMAC.
15. (15) Failure to train or supervise adequately supportive personnel or the use of supportive personnel in activities outside the scope of their permitted activities.
16. (16) Conviction, plea of nolo contendere, or entering into any other legal agreements for any violation of the Pharmacy Act, Controlled Substances Act, Drug Device and Cosmetic Act or any similar act of another state or territory of the United States.
17. (17) Suspension, revocation, denial, or forfeiture of license to practice or similar disciplinary action by a licensing agency of another state or territory of the United States.

18. (18) Dispensing a prescription for a dangerous drug to a patient without an established practitioner-patient relationship:

    1. (a) except for the provision of treatment of partners of patients with sexually transmitted diseases when this treatment is conducted in accordance with the expedited partner therapy guidelines and protocol published by the New Mexico department of health;
    2. (b) except for on-call practitioners providing services for a patient’s established practitioner;
    3. (c) except for delivery of dangerous drug therapies to patients ordered by a New Mexico department of health physician as part of a declared public health emergency;
    4. (d) except for dispensing the dangerous drug naloxone or other opioid antagonist as authorized in Section 24-23-1 NMSA 1978;
    5. (e) except for the prescribing or dispensing and administering for immunizations programs.
19. (19) Dispensing a prescription for a dangerous drug to a patient if the pharmacist has knowledge, or reasonably should know under the circumstances, that the prescription was issued on the basis of an internet-based questionnaire or an internet-based consultation without a valid practitioner-patient relationship.
20. (20) Failure to perform a prospective drug review as described in Subsection D of 16.19.4.16 NMAC and document steps taken to resolve potential problems.

21. (21) Acts or omissions within the provision of patient care including prescriptive authority, primary care, medication therapy management, collaborative practice, and monitoring dangerous drug therapy which fail to meet the standard of care.

    [3/1/1993; 16.19.4.9 NMAC - Rn, 16 NMAC 19.4.9, 3/30/2002; A, 7/15/2002; A, 1/15/2008; A, 9/16/2011; A, 8/31/2012; A, 3/23/2016; A, 10/19/2019; A, 11/13/2018; A, 9/13/2022; A, 5/07/2024; A, 11/05/2024]